Workflow
GINWA(600080)
icon
Search documents
金花股份:金花企业(集团)股份有限公司关于归还募集资金的公告
2024-12-02 07:37
证券代码:600080 股票简称:金花股份 编号:临 2024-052 金花企业(集团)股份有限公司 关于归还募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业(集团)股份有限公司(以下简称"公司")于 2023 年 12 月 5 日召开第十届董事会第六次会议、第十届监事会第五次会议,审议通过了《关于 使用部分闲置募集资金暂时补充流动资金的议案》,同意公司使用不超过人民币 4 亿元闲置募集资金暂时补充流动资金,主要用于与公司主营业务相关的经营活 动,使用期限自公司董事会审议批准之日起 12 个月内,到期前将及时、足额将 该部分资金归还至募集资金专户。具体内容详见 2023 年 12 月 7 日在上海证券报 及上海证券交易所网站披露的《关于使用部分闲置募集资金暂时补充流动资金的 公告》(公告编号:临 2023-061 号)。 2024 年 12 月 2 日,公司已将上述用于暂时补充流动资金的募集资金合计人 民币 282,830,721.57 元全部归还至公司募集资金专户,并将上述募集资金归还 情况通知 ...
金花股份:金花企业(集团)股份有限公司关于收到中国证券监督管理委员会陕西监管局《行政监管措施决定书》的公告
2024-11-29 10:28
证券代码:600080 股票简称:金花股份 编号:临 2024-051 金花企业(集团)股份有限公司 关于收到中国证券监督管理委员会陕西监管局 《行政监管措施决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业(集团)股份有限公司(以下简称"公司")于 2024 年 11 月 29 日收到中国证券监督管理委员会陕西监管局(以下简称"陕西监管局")《行政 监管措施决定书》(陕证监措施字【2024】43 号),陕西监管局对公司采取责 令改正措施并对公司相关责任人员采取出具警示函措施的决定,具体内容如下: 一、《行政监管措施决定书》内容 金花企业(集团)股份有限公司,邢雅江、韩卓军、孙明: 经查,你公司存在下列违规情形: (一)2023 年半年报、三季报财务信息披露不准确 你公司分别于 2023 年 6 月、8 月申购华银稳健成长 4 号私募基金 2,000 万 元、基成盈赢宝私募基金 1,000 万元,将其计入以公允价值变动且其变动计入当 期损益的金融资产中核算。你公司未按照《企业会计准则第 22 号—金 ...
金花股份:金花企业(集团)股份有限公司关于控股股东与部分一致行动人解除一致行动关系的提示性公告
2024-11-20 11:44
重要内容提示: 本次解除一致行动人关系不涉及各方实际持股数量的增减,系金花企业(集团) 股份有限公司(以下简称"公司"或"金花股份")控股股东、实际控制人邢博越及其 一致行动人与一致行动人之一钟春华解除一致行动关系,不触及要约收购。 证券代码:600080 股票简称: 金花股份 编号:临 2024-050 金花企业(集团)股份有限公司 关于控股股东与部分一致行动人解除一致行动关系的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并 对其内容的真实性、准确性和完整性承担个别及连带责任。 本次权益变动不会导致公司控股股东、实际控制人发生变化,邢博越仍为公司 控股股东、实际控制人。 2024 年 11 月 18 日,钟春华与邢博越、杜玲、杨蓓签订《解除一致行动人关系协议》, 主要内容如下: (1)钟春华自 2024 年 11 月 19 日起,在行使金花股份股东权利、履行股东义务中, 解除与邢博越、杜玲、杨蓓在《一致行动人协议书》项下的一致行动关系,不再与邢博 越、杜玲、杨蓓三方构成一致行动人。 解除一致行动关系后,邢博越与杜玲、杨蓓仍为一致行动人,合计持有公司 94,79 ...
金花股份(600080) - 2024 Q3 - 季度财报
2024-10-29 08:38
Financial Performance - The company's operating revenue for Q3 2024 was ¥172,965,736.96, representing a year-on-year increase of 17.32%[2] - Net profit attributable to shareholders for Q3 2024 was ¥21,307,271.49, a significant increase of 6,028.76% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥7,337,339.52, up by 181.78% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.0579, reflecting a year-on-year increase of 6,003.93%[2] - Net profit attributable to shareholders for the year-to-date period was ¥30,770,165.28, showing an increase of 807.59% compared to the same period last year[2] - Total operating revenue for the first three quarters of 2024 reached ¥418,931,219.77, an increase of 4.3% compared to ¥402,805,031.75 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was ¥30,770,165.28, significantly up from ¥3,390,298.30 in 2023, marking an increase of 807.4%[16] - Basic earnings per share for the first three quarters of 2024 were ¥0.0840, compared to ¥0.0091 in 2023, reflecting an increase of 823.1%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,859,779,651.33, a decrease of 11.80% compared to the end of the previous year[3] - As of September 30, 2024, the company's total assets amounted to approximately CNY 1.86 billion, a decrease from CNY 2.11 billion at the end of 2023, reflecting a decline of about 11.7%[11] - The company's cash and cash equivalents decreased significantly to CNY 260.92 million from CNY 620.45 million, representing a decline of approximately 58.1%[11] - Total current liabilities decreased to CNY 321.63 million from CNY 446.91 million, a reduction of about 28.1%[12] - The company's non-current liabilities decreased to CNY 18.45 million from CNY 23.22 million, a decline of approximately 20.1%[13] - The total equity attributable to shareholders decreased to CNY 1.52 billion from CNY 1.64 billion, reflecting a decrease of about 7.3%[13] Cash Flow - The company reported a net cash flow from operating activities of ¥22,340,708.43 for Q3 2024, a slight decrease of 0.45%[2] - The net cash flow from operating activities for the first three quarters of 2024 was -¥758,663.64, an improvement from -¥11,949,314.66 in 2023[17] - Cash outflow from investment activities totaled ¥854,957,088.85, a decrease from ¥1,495,491,250.16 in the previous period, resulting in a net cash flow from investment activities of -¥246,291,188.28 compared to -¥48,514,725.24[18] - Cash inflow from financing activities was ¥298,258,736.45, up from ¥175,405,390.44, while cash outflow from financing activities increased to ¥414,323,983.23 from ¥108,039,180.24, leading to a net cash flow from financing activities of -¥116,065,246.78 compared to ¥67,366,210.20[18] - The net increase in cash and cash equivalents was -¥363,115,098.70, contrasting with an increase of ¥6,902,170.30 in the previous period[18] - The ending balance of cash and cash equivalents was ¥256,617,682.97, down from ¥439,540,865.47[18] - The company reported a significant cash payment of ¥665,068,253.54 related to investment activities, compared to ¥1,313,316,947.02 in the previous period[18] Other Financial Metrics - The weighted average return on equity for Q3 2024 was 1.35%, an increase of 1.32 percentage points year-on-year[3] - Non-recurring gains for the current period totaled ¥13,969,931.97, with government subsidies contributing ¥3,462,487.62[5] - Research and development expenses increased to ¥20,283,032.38 in 2024, up from ¥8,860,272.09 in 2023, reflecting a growth of 128.5%[15] - Operating profit for the first three quarters of 2024 was ¥32,854,192.90, compared to ¥20,556,716.00 in 2023, representing a growth of 59.7%[15] - Total costs for the first three quarters of 2024 were ¥402,086,823.47, slightly up from ¥399,583,076.61 in 2023, indicating a marginal increase of 0.4%[15] - The company reported a significant increase in investment income, which rose to ¥31,783,964.82 in 2024 from ¥17,745,088.26 in 2023, an increase of 79.3%[15] - The company recorded a decrease in tax expenses to ¥1,687,076.42 in 2024 from -¥1,454,264.77 in 2023, indicating a positive shift in tax liabilities[16] - Other income increased significantly to ¥4,378,019.03 in 2024 from ¥222,350.42 in 2023, marking a growth of 1,967.5%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,641[8] - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending activities[10] - The company has not identified any significant changes in its operational situation during the reporting period[10] Accounting Standards - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[19]
金花股份:金花企业(集团)股份有限公司关于公司进行融资租赁的公告
2024-10-17 09:54
证券代码:600080 股票简称:金花股份 编号:临 2024-049 金花企业(集团)股份有限公司 关于公司进行融资租赁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 主要内容:金花企业(集团)股份有限公司 (以下简称"公司")拟 以公司自有医药生产制造设备为租赁标的,与浙江浙银金融租赁股份有限公司 (以下简称"浙银金租")开展融资租赁售后回租业务,融资总额不超过 2500 万元,主要用于设备采购,融资期限 24 个月。 本次融资租赁业务未构成关联交易,不构成《上市公司重大资产重组 管理办法》规定的重大资产重组。 该事项已经公司第十届董事会第十一次会议审议通过,无需提交股东 大会审议。 公司于 2024 年 10 月 17 日以通讯方式召开第十届董事会第十一次会议,审 议通过了《关于公司进行融资租赁的议案》。具体内容如下: 一、本次融资租赁概述 为拓宽融资渠道,确保资金需求,公司拟以公司自有医药生产制造设备为租 赁标的,与浙银金租开展融资租赁售后回租业务,融资总额不超过 2500 万元, 主要用 ...
金花股份:金花企业(集团)股份有限公司关于召开2024年半年度业绩说明会的公告
2024-09-06 09:31
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: https://roadshow.sseinfo.com/) 证券代码:600080 证券简称:金花股份 公告编号:临 2024-048 会议召开方式:上证路演中心网络互动 金花企业(集团)股份有限公司 投资者可于 2024 年 09 月 13 日(星期五)至 09 月 23 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 irm@ginwa.com.cn 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 关于召开 2024 年半年度业绩说明会的公告 金花企业(集团)股份有限公司(以下简称"公司")已于 2024 年 8 月 17 日发布公司 2024 年半年度报告,为便于广大投资者更全面深 入地了解公司 2024 年半年度经营成果、财务状况,公司计划于 2024 年 09 月 24 日下午 16:00-17:00 举行 2024 年半年度业绩说明会,就 投资者关心的问题进行交流。 董事会秘书:孙明 独立董事 ...
关于对金花企业(集团)股份有限公司及有关责任人予以监管警示的决定
2024-08-26 09:21
邢雅江,金花企业(集团)股份有限公司时任董事长。 上 海 证 券 交 易 所 上证公监函〔2024〕0196 号 关于对金花企业(集团)股份有限公司及 有关责任人予以监管警示的决定 当事人: 金花企业(集团)股份有限公司,A 股证券简称:金花股份,A 股证券代码:600080; 鉴于上述违规事实和情节,根据《股票上市规则》第 13.2.2 条 和《上海证券交易所纪律处分和监管措施实施办法》等有关规定, 我部作出如下监管措施决定: 对金花企业(集团)股份有限公司及时任董事长邢雅江予以监 管警示。 根据《上海证券交易所纪律处分和监管措施实施办法》,请你公 司及董事、监事和高级管理人员(以下简称董监高人员)采取有效 措施对相关违规事项进行整改,并结合本决定书指出的违规事项, 就公司信息披露及规范运作中存在的合规隐患进行深入排查,制定 针对性的防范措施,切实提高公司信息披露和规范运作水平。请你 公司在收到本决定书后一个月内,向我部提交经全体董监高人员签 字确认的整改报告。 你公司及董监高人员应当举一反三,避免此类问题再次发生。 公司应当严格按照法律、法规和《股票上市规则》的规定规范运作, 认真履行信息披露义务;董监高 ...
金花股份:金花企业(集团)股份有限公司关于收到中国证券监督管理委员会陕西监管局行政监管措施决定书的公告
2024-08-23 14:08
证券代码:600080 股票简称:金花股份 编号:临 2024-046 金花企业(集团)股份有限公司 关于收到中国证券监督管理委员会陕西监管局 经核查举报线索,发现你公司董事长邢雅江因涉嫌犯罪于 2024 年 4 月至 7 月被公安机关采取了取保候审的刑事强制措施。该事项属于应立即披露的重大事 件,但你公司至今未披露,违反了《上市公司信息披露管理办法》(证监会令第 182 号,以下简称《办法》)第二十二条第一款、第二款第一项的规定。邢雅江 作为上市公司董事长和事件当事人,违反了《办法》第三十三条第一款规定。 根据《办法》第五十二条规定,我局决定对你公司及邢雅江采取责令改正的 行政监管措施,责令你们在收到本决定书后立即披露邢雅江被采取刑事强制措施 的具体情况,说明事件起因、最新进展及对公司的影响等。你们应认真汲取教训, 严格遵守上市公司信息披露各项规定,杜绝此类行为再次发生,并自收到本决定 书之日起十五个工作日内分别向我局提交书面整改报告。 行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业 ...
金花股份:金花企业(集团)股份有限公司关于公司董事长被采取取保候审措施并收到解除取保候审决定书的公告
2024-08-23 14:08
金花企业(集团)股份有限公司(以下简称"公司")于 2024 年 8 月 23 日 收到董事长邢雅江先生送达的《解除取保候审决定书》,知悉董事长邢雅江先生 于 2024 年 4 月 23 日至 2024 年 7 月 26 日期间被公安机关采取取保候审的措施, 具体情况如下: 一、事件的起因及进展 经公司向邢雅江先生核实,前期因其他人员涉嫌私自刻制与公司无关的其他 公司印章被公安机关立案调查,其向公安机关供述系邢雅江先生知悉并受其指 使,致使邢雅江先生成为涉案人员,西安市公安局鄠邑分局于 2024 年 4 月 23 日起决定对董事长邢雅江先生取保候审。 2024 年 7 月 26 日,西安市公安局鄠邑分局出具了《解除取保候审决定书》, 因指证邢雅江的证据发生变化,现有证据不能证实邢雅江有涉案嫌疑,根据《中 华人民共和国刑事诉讼法》第七十九条第二款之规定,决定予以解除取保候审。 证券代码:600080 股票简称:金花股份 编号:临 2024-047 金花企业(集团)股份有限公司 关于公司董事长被采取取保候审措施并收到解除取保候审 决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 ...
金花股份(600080) - 2024 Q2 - 季度财报
2024-08-16 09:17
Financial Performance - The company's operating revenue for the first half of 2024 was approximately CNY 245.97 million, a decrease of 3.68% compared to the same period last year[25]. - The net profit attributable to shareholders for the first half of 2024 was approximately CNY 9.46 million, an increase of 211.01% year-on-year[25]. - Basic earnings per share for the first half of 2024 were CNY 0.0261, representing a 218.20% increase compared to CNY 0.0082 in the same period last year[25]. - The weighted average return on net assets increased to 0.60%, up by 0.42 percentage points from the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 10.03 million yuan, a decrease of 42.39% compared to the previous year[41]. - The company reported a significant increase in investment income, which rose to CNY 29,401,390.85 from CNY 18,469,690.53, an increase of 59.5%[163]. - The company reported a total comprehensive income of CNY 1,097,818.35 for the first half of 2024, down from CNY 4,317,849.32 in the previous year[171]. Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 1.79 billion, down 15.21% compared to the previous year[25]. - The net assets attributable to shareholders at the end of the reporting period were approximately CNY 1.50 billion, a decrease of 8.55% from the end of the previous year[25]. - Total liabilities decreased to CNY 288,448,334.75 from CNY 455,489,966.11, indicating a reduction of 36.7%[158]. - The company's total equity stood at CNY 1,505,660,295.42, down from CNY 1,654,062,384.09, reflecting a decrease of 9.0%[158]. Cash Flow - The company reported a net cash flow from operating activities of CNY -23.10 million, indicating a decline in cash flow compared to CNY -34.39 million in the previous year[25]. - Cash flow from operating activities showed a net outflow of CNY 23,099,372.07, an improvement from a net outflow of CNY 34,391,321.39 in the same period last year[182]. - Cash inflow from financing activities was CNY 298,234,856.45, significantly higher than CNY 99,000,000.00 in the previous year, marking a 201.36% increase[182]. Research and Development - The company's research and development expenses increased by 60.93% to ¥8,421,920.46 from ¥5,233,339.12 year-on-year[57]. - Research and development expenses increased to CNY 8,421,920.46 in the first half of 2024, up from CNY 5,233,339.12 in the previous year, representing a growth of 60.5%[163]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of various drug types[35]. - The company has established a strong position in the pharmaceutical industry, focusing on orthopedics, immunology, and pediatrics, with key products like artificial tiger bone powder and Jintian Ge capsules recognized in 47 authoritative guidelines[42]. - The marketing strategy includes academic promotion and collaboration with authoritative organizations, enhancing clinical evidence and product application in medical institutions[44]. Compliance and Risk Management - The company is currently facing ongoing arbitration related to a guarantee provided by a former controlling shareholder, which has not yet been resolved[9]. - The company has established a risk management group to enhance safety management and ensure compliance with quality standards in production[53]. - The company is focusing on compliance management to reduce potential risks and protect its rights[56]. Environmental Management - The company has not reported any significant environmental issues or administrative penalties related to environmental protection during the reporting period[85]. - The company’s emissions of nitrogen oxides from combustion waste meet the required standards[85]. - The company has established a comprehensive environmental monitoring system, ensuring all pollutants are within the emission standards[95]. Shareholder and Equity Management - The company committed to not increasing its equity stake in the listed company for the next 12 months, based on market conditions and business development[100]. - The company has a plan to reduce its holdings of up to 3,982,690 shares, representing 1.07% of the total share capital, through block trading and centralized bidding within the next 12 months[103]. - The company has completed its commitment to not increase or decrease its equity stake in the listed company as of April 23, 2025[103].